January 23, 2017 / TheNewswire / Vancouver, British Columbia – AREV Nutrition Sciences Inc. previously Immunall Sciences Inc  (the “Company” or “AREV”)  (CSE: ARV) is pleased to announce today that its shares will commence trading on the CSE under the symbol ARV. Shares issued and outstanding are 11,913,200.

 

The company recently acquired one of the most sophisticated and advanced Fast Freeze Extraction (FFE) technologies currently on the market.  Operating at lower temperatures, the extraction process preserves vital ingredients while yielding extracts of superior quality with no undesirable by-products. This FFE system can be used on many different biomass types and operates using non-hydrocarbon gas or solvents, including Cannabis in accordance with Health Canada.

 

AREV owns an innovative line of emulsified 100% coconut derived MCT oil combined with Whey Protein to serve as base ingredients. The product line trademarked as COCO-MULSION, will be sold on line and distributed through Natural Health and Sport Nutrition stores. The COCO-MULSION products have been registered with Health Canada and target specific health benefits. The first two products to be released for distribution in February 2017 are the COCO-MULSION Original (providing a boost of energy and antioxidants) and COCO-MULSION Brain (improving cognitive behavior). The Original emulsion can also be used by pharmacies and dispensaries as an alternative means of dispensing Cannabis oils.

Production of the products has started and Canadian distribution is ready for February 2017. AREV will be exhibiting at the Natural Product Expo West (North American’s largest trade show for Natural Products) in Anaheim, California on March 2017.

AREV owns patent rights for a Method and Composition for Preventing and Treating Avian Influenza in Poultry, for which Letters Patent of the United States issued on December 23, 2014, U.S. Patent No. 8,916,211 (the “Poultry Patent.”). This patent is leverage on the Ginse® ingredient the company owns and may be licensed to customers of the meal by product created from the extraction methods.

 

Meet the Board of Directors.

 

The current members of the board of directors of the Company are Mr. Stephane Maher, Mr. Mike Withrow, Dr. Nils Rehmann and Mr. Scott McDermid.

 

Mr. Stephane Maher became director, Chief Executive Officer and Interim Chief Financial Officer of AREV on March 29, 2016. He holds a B.A. in Communication with a minor in Marketing from Laval University. Mr. Maher is an independent contractor of the Company. Mr. Maher founded Yellow Brick Sales and Marketing Group Inc. (“Yellow Brick”) in 2002, and has served as President of Yellow Brick since that time. Yellow Brick is a consulting company that helps manufacturers, importers and retailers of natural health products to achieve regulatory compliance in Canada. Yellow Brick is not an affiliate of AREV. Through his work at Yellow Brick, Mr. Maher has gained extensive experience in the nutraceutical industry – particularly with respect to the regulatory regime that applies to the production, importation, manufacture, distribution and sale of natural health products in Canada. Mr. Maher is not an independent director as he currently serves as Chief Executive Officer and interim Chief Financial Officer of the Company.

 

Mr. Mike Withrow became a director and Chairman of the Board of Directors of the Company on November 13, 2016. Mr. Withrow served as Chief Executive Officer of Arcturus Growthstar Technologies Inc. from May 2015 to August 2016 and as Chief Executive Officer of Abattis Bioceuticals Corp. from February 2011 to February 2015. Mr. Withrow has been involved in early stage structuring and development of bio­tech and nutraceutical companies over the past 10 years. During this time, Mr. Withrow served as Vice President of Business Development of two nutraceutical companies with commercialized products in the market. He has an in-depth knowledge of Intellectual Property and the patent process, supplement innovation, ingredients and is well connected in the ingredients and natural health product industry and vast network of professionals in the medicinal botanical industry. Mr. Withrow serves as a Board Member of the Saskatoon Berry Council of Canada, and brings with him with over 25 years experience in public markets. Mr.Withrow is a control person of the Company and currently serves as Chairman of the Board of Directors of the Company. Mr. Withrow is not an independent director of the Company as he is Chairman of the Board of Directors of the Company and is a control person of the Company.

 

Dr. Nils Rehmann became a director of the Company on March 29, 2016. He holds a Ph.D.in Pharmacology and Toxicology from the University College Dublin, Ireland, and a Chem.-Eng. Degree from the University of Applied Sciences Fresnius, Germany. Dr. Rehmann works part-time for AREV. He devotes as much time as is necessary to fulfill his obligations to the Company. Dr. Rehmann is an independent contractor of the Company. Since 2013, Dr. Rehmann has owned and operated Nirem Consulting Inc. (“NiRem”), a consulting company that advises clients in the biotechnology, research and development, and life sciences sectors on methods to improve laboratory performance, business development and regulatory compliance, and assisting firms in achieving accreditation under International Standards Organization (ISO) and Good Manufacturing Practices (GMP). Prior to founding NiRem, from 2008 to 2013, Dr. Rehmann worked as a method development chemist for the Research and Productivity Council of New Brunswick (“RPCNB”). In this role, he was involved in developing nutritional labelling analysis and food safety regulatory analysis methods. In his roles at NiRem and RPCNB, Dr. Rehmann has gained extensive experience in the nutraceutical industry – particularly with respect to the regulatory regime that applies to the nutritional labelling and safety accreditation of natural health products in Canada. Dr. Rehmann’s educational background and work experience has also provided him with insight into methods to improve research strategies and laboratory performance involved in the development of nutraceutical products. Dr. Rehmann is an independent director of the Company.

 

Mr. Scott McDermid became a director of the Company on November 10, 2016. Mr. McDermid currently serves as a director of Arcturus Growthstar Technologies Inc. and has served in that capacity since September 2015. Mr. McDermid is a businessman with over 30 years of experience in the real estate industry. He is a licensed commercial realtor and has extensive knowledge in the building and property management business. He is also a licensed property manager as well as a licensed builder. Mr. McDermid is an independent director of the Company.

 

For further information, contact Stephane Maher at 604.868.5013.

 

On behalf of the Board,

 

AREV Nutrition Sciences Inc.

 

“Stephane Maher”

 

CEO and Director

 

About AREV Nutrition Sciences Inc.

AREV produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil and whey protein through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, and bioceutical markets.  AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts.

  

The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and have neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under applicable securities laws.